2019
DOI: 10.1177/0300060519887637
|View full text |Cite
|
Sign up to set email alerts
|

Bioinformatics analysis reveals 6 key biomarkers associated with non-small-cell lung cancer

Abstract: Objective Non-small-cell lung cancer (NSCLC) accounts for >85% of lung cancers, and its incidence is increasing. We explored expression differences between NSCLC and normal cells and predicted potential target sites for detection and diagnosis of NSCLC. Methods Three microarray datasets from the Gene Expression Omnibus database were analyzed using GEO2R. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analysis were conducted. Then, the String database, Cytoscape, and MCODE plug-in were … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
8
0

Year Published

2020
2020
2022
2022

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(8 citation statements)
references
References 37 publications
(43 reference statements)
0
8
0
Order By: Relevance
“…14 Furthermore, Dai detected multiple genes that are abnormally expressed in patients with NSCLC and used bioinformatic analysis to identify hub genes as potential early diagnosis and treatment biomarkers. 15…”
Section: Introductionmentioning
confidence: 99%
“…14 Furthermore, Dai detected multiple genes that are abnormally expressed in patients with NSCLC and used bioinformatic analysis to identify hub genes as potential early diagnosis and treatment biomarkers. 15…”
Section: Introductionmentioning
confidence: 99%
“…In 2020, Maharjan et al, using bioinformatics analysis, identified 16 biomarkers for lung cancer including Cyclin-B2 (CCNB2), Cell Division Cycle 20 (CDC20), F-Box And Leucine Rich Repeat Protein 3 (FBXL3), and Forkhead Box A2 (FOXA2) [ 20 ]. Dai et al identified CDC20, ECT2, MKI67, TPX2, and TYMS as biomarkers using microarray analysis, where Cell Division Cycle 20 (CDC20), Epithelial Cell Transforming 2 (ECT2), Marker of Proliferation Ki-67 (MKI67), TPX2 Microtubule Nucleation Factor (TPX2), and Thymidylate Synthetase (TYMS) showed worse survival outcome [ 21 ]. Few studies reveal that Cyclin A2 (CCNA2) and Neuromedin U (NMU) were involved with diagnosis and prognosis of NSCLC [ 22 , 23 ].…”
Section: Discussionmentioning
confidence: 99%
“…Bioinformatics analysis has rapidly increased in the last few years for discovering new therapeutic targets and biomarkers for several cancers [19]. showed worse survival outcome [21]. Few studies reveal that Cyclin A2 (CCNA2) and Neuromedin U (NMU) were involved with diagnosis and prognosis of NSCLC [22,23].…”
Section: Discussionmentioning
confidence: 99%
“…In adenocarcinomas, for instance, the selected CellDiv features in terms of nuclear solidity and mean inside boundary showed higher expression of genes related to the biological pathway of DNA replication 32 and nucleus development. 33 With the CellDiv features essentially capturing the degree of heterogeneity and diversity in shape, size, and texture of cancer nuclei, this seems to suggest that higher expression of those developmental pathways leads to more disordered or chaotic nuclei. Meanwhile, in LUSC, the family of bone morphogenetic protein and transforming growth factor β receptors, which have been already shown to be implicated in lung cancer carcinogenesis, 34 were found to be associated with CellDiv features that measuring nuclear shape and intensity, clearly suggesting that the diversity features are being driven by the cellular differentiating and adhesion pathways.…”
Section: Discussionmentioning
confidence: 99%